Dr. Kanti Rai is the founder of the Rai Clinical Staging System for CLL, published in 1975. In 2000, he produced the definitive comparative study of chlorambucil and fludarabine in the treatment of the CLL patient. Subsequently, he studied the combined use of fludarabine and cytoxan, the combined use fludarabine and rituximab, and the combination of all three. He has also been at the forefront of defining many of the molecular prognostic markers that have emerged in the last few years and of defining the molecular lesions involving mir15/mir16a associated with the 13q14 deletion in CLL. Insert introduction from collected works page or other prepared intro here.
Dr. Rai was Born in Jodhpur, India, and is a graduate of Sawai ManSingh (SMS) Medical College, University of Rajasthan, in Jaipur. He began his early medical training in pediatric medicine at Lincoln Hospital and North Shore University Hospital in New York. He completed a fellowship in hematology and nuclear medicine at Long Island Jewish (LIJ) Medical Center. He went on to join the Hematopoetic Cell Kinetics research team at the Brookhaven National Laboratory (BHL). Dr. Rai has been a member of ASCO since 1970. He is a member of the board of directors for the CLL Research Consortium (CRC), a founding member of iwCLL, and member of the Cancer and Leukemia Group B (CALGB). In 2006, he served as the president of the American Society of Hematology.